spasticity

Nabiximols and other cannabis-based preparations sometimes used with multiple sclerosis (MS) appear to work well for controlling spasticity, a common disease symptom that occurs when muscles stiffen or tighten, a meta-analysis of findings in published studies reported. Larger studies into cannabis-based treatments of spasticity for these patients…

Noninvasive brain stimulation (NIBS) may be able to reduce fatigue, spasticity, and pain, and improve quality of life in patients with multiple sclerosis (MS), a new meta-analysis reports. The review assessed several NIBS interventions targeting different brain regions. The results suggest that these techniques can have immediate effects…

Four weeks of treatment with nabiximols — an oral spray containing compounds found in the cannabis plant — significantly reduced spasticity and generally improved arm and hand function in multiple sclerosis (MS) patients with moderate-to-severe spasticity, according to a small pilot study in Italy. Notably, after nabiximols, patients showed…

Electrical stimulation of the brain through electrodes placed on the scalp may ease some measures of spasticity for people with relapsing-remitting multiple sclerosis (RRMS), according to results from a small clinical trial. Using this novel route of brain stimulation was shown to impact muscle contractions in patients with spasticity…

School started last week for our three kids. They got to see friends from the last school year, meet their new teachers, and sit at a new desk in their new classrooms. Per tradition, there was no homework assigned the first week, but they still brought home plenty of papers…

An assistive device made it significantly easier and more comfortable for multiple sclerosis (MS) patients with arm and hand mobility problems to self-administer nabiximols — an oral spray containing compounds found in the cannabis plant — a study found. Trained nurses involved in the study agreed with its…

Lyvispah — a dissolvable granular formulation of baclofen — is now commercially available in the U.S. for adults and adolescents, 12 and older, with spasticity associated with multiple sclerosis (MS) and other spinal cord disorders. In people with MS, the strawberry-flavored formulation is particularly suitable to ease flexor…

More than half of Canadians with multiple sclerosis (MS) report using cannabis to help manage their symptoms, according to a new study. The study, “Medical cannabis use in Canadians with multiple sclerosis,” was published in Multiple Sclerosis and Related Disorders. Humans have used the cannabis plant for millennia,…

#ACTRIMS2022 – Immune System ‘Reset’ by Stem Cell Transplant At the University of Ottawa, autologous hematopoietic stem cell transplantation (aHSCT) has been used to treat people with aggressive MS since the early 2000s, MS News Today‘s Marisa Wexler reports. This study, which reviewed 71 patients during that period, reports…

Multiple sclerosis (MS) patients who experience reductions in spasticity after a four-week course of inpatient rehabilitation can sustain those improvements in the long term using an app-based self-training program, according to data from a clinical trial. The app also led to better adherence to the self-training program than…

The U.S. Food and Drug Administration (FDA) has approved Lyvispah, a dissolvable granular formulation of baclofen, to treat spasticity in people with multiple sclerosis (MS). The strawberry-flavored formulation, developed by Saol Therapeutics, is particularly suitable to ease flexor spasticity, the involuntary bending of the knees and hips toward the…

I have to admit, I’ve wheeled down the THC path a few times before. Yes, I know it’s very difficult to stay on the path when under the influence. Luckily, I’ve solved this problem by only imbibing in bed. I say imbibing, because for me, smoking the stuff is…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Four…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Sativex…

“You’re my summer that fades/ To these cold autumn days/ You’re my keepsake, my friend, and my fears/ You’re the strength that’s inside and I swear on my life/ I will always be there by your side.” — Amber Pacific Autumn has always been my favorite time of year. I…

Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to start this year, the RELEASE MSS5…

Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or…

Medical cannabis made by Panaxia Labs Israel will be marketed and distributed in Greece by Leriva Group, under a recent agreement between the two companies and pending a marketing authorization in the country. The product will be sold under the brand name Panaxir. The companies expect to start…

Treatment of up to a year with memantine — an approved therapy for Alzheimer’s disease — failed to prevent cognitive decline and disability, and to significantly reduce fatigue and spasticity in adults with multiple sclerosis (MS), a review of published studies shows. The therapy, sold under the brand name Namenda, works…

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is…

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS). Sativex, by…

The U.S. Food and Drug Administration (FDA) has agreed to review  Osmotica Pharmaceuticals‘ amended request for the approval of arbaclofen extended release (ER) tablets to treat spasticity in people with multiple sclerosis (MS), the company announced.

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other…

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name…

Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to…

Nimodipine, an approved medication to prevent brain damage caused by hemorrhage, can be used to prevent spasticity following a spinal cord injury, a mouse study shows. In addition to spinal cord injury, nimodipine may be a promising treatment for neurodegenerative disorders such as multiple sclerosis (MS) and…

About 85% of people with multiple sclerosis (MS) using cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in…

Sativex (nabiximols), a THC:CBD oral spray, consistently relieves the pain and severity of treatment-resistant spasticity in multiple sclerosis (MS) patients, according to a recent study. An analysis of the Sativex as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) study revealed that Sativex, used in…

I have secondary progressive multiple sclerosis and I am rare. In honor of Rare Disease Day on Feb. 29, I honor myself. I honor you and anyone else with a rare disease. I have been asked if multiple sclerosis qualifies as a rare disease. It does if…

  The U.S. Food and Drug Administration (FDA) has granted approval to Flowonix Medical’s Prometra II Programmable Pump System for use with intrathecal baclofen for the treatment of spasticity across numerous conditions, including multiple sclerosis. Intrathecal baclofen — sold as Gablofen by Piramal, Lioresal by…